OncLive SOSS

Authors

Sandra Demaria, MD

Latest:

Dr. Sandra Demaria on Radiation and Immunotherapy Combination Regimens

Sandra Demaria, MD, assistant professor of Radiation Oncology, (Interim), Radiation Oncology, Weill Cornell Medical College and New-York Presbyterian, discusses the synergy with radiation therapy and immunotherapy as a potential combination regimen for patients with cancer.

Latest:

IDO Inhibitor/Chemo Combo Shows Early Promise in Advanced Pancreatic Cancer

Nathan Bahary, MD, discusses results of a study that showed that the combination of indoximod with standard chemotherapy yielded a response rate of 42% as a first-line therapy for patients with metastatic pancreatic adenocarcinoma.

Latest:

Immunotherapy Shows Early Promise in Advanced Sarcomas

Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.

Sandra Kelly, RN, MS, NP, Nurse Practitioner Brigham & Womenâ€™s Hospital

Latest:

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Sandra M. Swain, MD

Latest:

HER2-low Breast Cancer: Practical Applications of ADC Therapy

Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.

Sandra P. Dâ€™Angelo, MD

Latest:

Novel Molecular Targets for Drug Development in Non-GIST Sarcomas

The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these diseases.

Sandra P. D'Angelo, MD

Latest:

Dr D'Angelo on the Significance of Lete-Cel Treatment Across Sarcoma Subtypes

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

Sandy Srinivas, MD, Stanford University Medical Center

Latest:

Dr Srinivas on the Role of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.

Sandy Truong, Harvard Medical School studentÂ

Latest:

ï»¿Improving Cancer Survivorship: Embedding Tailored, Comprehensive Survivorship Care in the Breast Oncology Clinic

Ann Partridge, MD, MPH, from Dana-Farber Cancer Institute and Sandy Truong, a Harvard Medical School student, discuss the needs of cancer survivors and their efforts to optimize survivorship care.

Latest:

Dr. Wong on Treatment Goals in Systemic Amyloidosis

Sandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.

Sangeetha Palakurthi, PhD

Latest:

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).

Sanjay Popat, PhD, FRCP, Imperial College London

Sanjay Popat, PhD, FRCP, The Royal Marsden Hospital

Latest:

Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLC

Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.

Sanjaya K. Satapathy, MD

Latest:

Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCC

Sanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.

Sanjeeva P. Kalva, MD

Latest:

Liver-Directed Therapy for Hepatic Malignancies

Management of hepatic malignancies requires a multidisciplinary approach, and is based on the tumor burden, liver function, and PS of the patient.

Sanjiv S. Agarwala, MD

Latest:

Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 Blockade

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.

Sanjiv S. Agarwala, MD, Temple University School of Medicine

Santhosh Upadhyaya, MD

Latest:

Dr. Upadhyaya Discusses Drug Development for Pediatric Patients With Brain Tumors

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors.

Santiago Sherwell-Cabello, MD

Latest:

Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBC

Santiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).

Sara A. Hurvitz, MD

Latest:

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.